MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Nanomedicine

Background:

• Adrenocortical carcinoma (ACC) presents a poor prognosis with limited treatment options.
• Current challenges in ACC therapy include late diagnosis, metastasis, and resistance to conventional treatments.
• Systemic delivery of microRNAs (miRNAs) as a novel therapeutic strategy faces significant hurdles.

Purpose of the Study:

• To investigate the therapeutic potential of microRNA-7-5p (miR-7) replacement in adrenocortical carcinoma.
• To evaluate the efficacy of systemic miR-7 delivery using EGFREDVTM nanocells in preclinical ACC models.
• To elucidate the molecular mechanisms underlying miR-7's anti-tumorigenic effects in ACC.

Main Methods:

• In vitro assessment of miR-7's effects on ACC cell proliferation and cell cycle.
• In vivo evaluation of systemic miR-7 administration via EGFREDVTM nanocells in ACC xenograft models.
• Analysis of miR-7 targets (RAF1, MTOR) and downstream effects (CDK1) in ACC cells and patient samples.

Main Results:

• miR-7 significantly reduced ACC cell proliferation and induced G1 cell cycle arrest in vitro.
• Systemic miR-7 delivery via EGFREDVTM nanocells suppressed ACC xenograft growth.
• miR-7 targets RAF1 and MTOR, and inhibits CDK1, which is overexpressed in patient ACC samples with inverse miR-7 expression.

Conclusions:

• miR-7 acts as a tumor suppressor by inhibiting multiple oncogenic pathways in ACC.
• Systemic delivery of miR-7 using EGFREDVTM nanoparticles is a viable therapeutic approach for ACC.
• This study provides the first evidence for miRNA replacement therapy as a novel strategy against ACC.